Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 9/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 5/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650105 | 0.92 | BLM (0.41) | BLMMEN1KMT2APOLBMAPT | |
| SCHEMBL13650083 | 0.90 | CFTR (0.49) | MEN1KMT2APOLBHIF1ANPC1 | |
| SCHEMBL13650086 | 0.85 | MEN1 (0.45) | BLMMEN1KMT2APOLBCHEK1 | |
| SCHEMBL13650099 | 0.84 | MEN1 (0.44) | BLMMEN1KMT2APOLBCHEK1 | |
| SCHEMBL13650106 | 0.77 | SIRT1 (0.49) | MEN1KMT2APOLBMAPTLMNA | |
| SCHEMBL13650092 | 0.77 | SIRT1 (0.48) | MEN1KMT2APOLBMAPTLMNA | |
| SCHEMBL13650095 | 0.76 | MEN1 (0.43) | MEN1KMT2APOLBCHEK1AURKA | |
| SCHEMBL13650085 | 0.74 | CFTR (0.56) | MEN1KMT2APOLBNPC1 | |
| SCHEMBL12648526 | 0.74 | MAPT (0.66) | BLMMEN1KMT2APOLBCHEK1 | |
| SCHEMBL13650098 | 0.74 | CFTR (0.53) | MEN1KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | BLM 1540/4885MEN1 4189/4885KMT2A 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.